Reverse-payment patent settlements in the pharmaceutical industry: An analysis of US antitrust law and EU competition law

Damien Geradin, Michael Clancy, Andrew Lazerow

    Research output: Contribution to journalArticleScientificpeer-review

    Original languageEnglish
    Pages (from-to)153-172
    Number of pages20
    JournalAntitrust Bulletin
    Volume59
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Cite this

    @article{db6869306e094d82a72056a071c88e10,
    title = "Reverse-payment patent settlements in the pharmaceutical industry: An analysis of US antitrust law and EU competition law",
    author = "Damien Geradin and Michael Clancy and Andrew Lazerow",
    year = "2014",
    doi = "10.1177/0003603X1405900107",
    language = "English",
    volume = "59",
    pages = "153--172",
    journal = "Antitrust Bulletin",
    issn = "1930-7969",
    number = "1",

    }

    Reverse-payment patent settlements in the pharmaceutical industry : An analysis of US antitrust law and EU competition law. / Geradin, Damien; Clancy, Michael; Lazerow, Andrew.

    In: Antitrust Bulletin, Vol. 59, No. 1, 2014, p. 153-172.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - Reverse-payment patent settlements in the pharmaceutical industry

    T2 - An analysis of US antitrust law and EU competition law

    AU - Geradin, Damien

    AU - Clancy, Michael

    AU - Lazerow, Andrew

    PY - 2014

    Y1 - 2014

    U2 - 10.1177/0003603X1405900107

    DO - 10.1177/0003603X1405900107

    M3 - Article

    VL - 59

    SP - 153

    EP - 172

    JO - Antitrust Bulletin

    JF - Antitrust Bulletin

    SN - 1930-7969

    IS - 1

    ER -